# P30 Cancer Center Support Grant Electronic Data (eData) Guide v3.1.2

National Institutes of Health/ DHHS
National Cancer Institute
Office of Cancer Centers

9609 Medical Center Drive Rockville, MD 20850

http://cancercenters.cancer.gov

# **CONTENTS**

INTR(	ODUCTION	1
BACKGRO	OUND	1
	E	
OCC DAT	TABASE	1
REFEREN	ICES	3
SECTI	ION 1. DATA TABLES 1A, 1B, 1C, AND 1D	4
1.1	DATA TABLE 1A - SENIOR LEADERSHIP	
1.2	DATA TABLE 1B - PROGRAMS, LEADERS, AND PROGRAM CODES	5
1.3	DATA TABLE 1C - SHARED RESOURCES	10
SECTI	ION 2. DATA TABLES 2A AND 2B - ACTIVE FUNDED PROJECTS.	9
2.1	DATA TABLE 2A - ACTIVE FUNDED PROJECTS	
2.2	DATA TABLE 2B- ACTIVE FUNDED PROJECTS	
SECTI	ION 3. DATA TABLE 3 - NEWLY REGISTERED PATIENTS/PART	ICIDATION OF
	ENTS IN INTERVENTIONAL TREATMENT TRIALS BY	
<b>Д</b> АТА ТА	ABLE 3 - EXAMPLE FORMAT	15
SECTI	ION 4. DATA TABLE 4 - INFORMATION ON CLINICAL RESEARC	CH STUDIES 17
APPE	NDIX A. DATA TABLE EXAMPLE FORMAT	A
<b>Д</b> АТА <b>Т</b> А	ABLE 1A EXAMPLE FORMAT	1
<b>ДАТА ТА</b>	ABLE 1B EXAMPLE FORMAT	2
<b>ДАТА ТА</b>	ABLE 1C EXAMPLE FORMATERROR! BO	OOKMARK NOT DEFINED.
	ABLE 2A - EXAMPLE FORMAT	
DATA TA	ABLE 2B EXAMPLE FORMAT	8
DATA TA	ABLE 4 - EXAMPLE FORMAT	9
APPE	NDIX B. SUMMARY OF CHANGES TO EDATA	B
	-1: SUMMARY OF CHANGES TO EDATA	
FIGUI	RES	
El	TIGLIDE 1. THE DATA TABLE I/O OVERVIEW FDDON POOKMAR	V NOT DEFINED

## **TABLES**

FIGURE 1: THE DATA TABLE I/O OVERVIEW	ERROR! BOOKMARK NOT DEFINED.
TABLE 1: OVERVIEW OF DATA TYPES	2
TABLE 1-1: DATA TABLE 1A COLUMN DEFINITIONS	4
TABLE 1-2: DATA TABLE 1B COLUMN DEFINITIONS	5
TABLE 1-3: DATA TABLE 1C COLUMN DEFINITIONS	7
TABLE 2-1: DATA TABLE 2A COLUMN DEFINITIONS	
TABLE 2-2: DATA TABLE 2B COLUMN DEFINITIONS	12
TABLE 3-1: DATA TABLE 3 COLUMN DEFINITIONS	13
TABLE 4-1: DATA TABLE 4 COLUMN DEFINITIONS	

#### INTRODUCTION

#### **Background**

The Office of Cancer Centers (OCC) of the National Cancer Institute (NCI) is responsible for overseeing a portfolio of Cancer Center Support Grants (CCSG) that support cancer research at NCI-designated Cancer Centers across the U.S. The Centers program was established by the 1971 National Cancer Act and serves as a major platform for advancing NCI initiatives.

The CCSG Data Tables itemize the Center's formal Research Programs, Shared Resources, base of funded research projects, patient information, clinical research protocols, and current and requested budgets. The primary reason for standardized Data Tables is to ensure consistency and thoroughness during the peer review of competing applications. Additionally, the Data Tables are used to assess center progress, generate reports, and produce benchmark data on the Centers program.

Each year, 60 days prior to the award anniversary date, the Centers are required to send an electronic copy of the Data Tables (1-4) in Excel format directly to the OCC at <a href="mailto:ccsgdata@mail.nih.gov">ccsgdata@mail.nih.gov</a>. Per NIH policy, T2 applications serve as the progress report for the fiscal year in which the application is newly funded. Although no separate RPPR need be submitted 60 days prior to the start date of the newly funded award, eData 1-4 must still be submitted at that time.

The data submitted by all NCI-designated Cancer Centers are verified for consistency and imported into the OCC SQL-Server database. In addition, the aggregate Data Tables, detailed data and reports are presented on the OCC website, <a href="http://cancercenters.cancer.gov">http://cancercenters.cancer.gov</a>. The figure 1-1 shows the overview of the input and output (I/O) of the Data tables:




Figure 1: The Data Tables Data Flow Diagram

#### **Purpose**

The purpose of the CCSG Electronic Data Guide, herein referred to as eData Guide, is to present a description and standard format for the submission of electronic data. This format will allow Centers' data to be processed and shared in a uniform and consistent matter. The eData Guide seeks to accomplish the following:

- Facilitate data standardization
- Streamline the data importing process
- Improve data quality and analysis
- Simplify data management and reporting

This eData Guide is meant as a specific guide for the eData submission and describes each of the data table's field columns at a granular level with significant technical detail. It identifies each data column, definition, type and its usage; it also includes example(s) for each of the data tables. The CCSG Data Guide should be consulted in order to derive background information regarding the purpose of each Data Table and to prepare the Data Tables that accompany Type 1 and Type 2 competitive applications.

Data Table 5 is not required to be submitted electronically; therefore, it is excluded from this document.

#### **OCC Database**

As a step toward improving web interactivity, the existing OCC website has been redesigned to a more dynamic or database-driven website. The centralized database that supports this enhanced website application is where all the tables, views, stored procedures, user defined functions, and triggers are created.

Tables are commonly referred to as entities in the database. Data columns (fields) are commonly referred to as attributes for a table. In the OCC database, the underscore character will not be used in a table name or column name. Furthermore, all tables in the OCC databases will begin with an uppercase letter followed by a series of upper and lowercase letters. Meaningful table names have been chosen to identify the overall purpose of the database tables (*e.g.*, P30Partner).

Each data column in the table has a data type, which defines what kind of data can be stored in a column.

**Note** the distinction between a blank space and a NULL value. A blank space is a character string while a NULL is an unknown value. If the data is not available or applicable, use NULL by leaving the column empty.

Table 1-1 provides an overview of data types that are used in the OCC database.

**Table 1: Overview of Data Types** 

Data Type	Abbr	Syntax	Valid Entry	Description
Character	Char	Char(n)	A character or NULL value	Fixed-length, non-Unicode string data. n defines the string length and must be a value from 1 through 8,000. It is used for data that are a mixture of numbers and letters (alphanumeric data).
Datetime	-	DateTime	Date/time or NULL value	Stores exact date/time values
Varchar [ ( n   max ) ]	-	Varchar(n), or Varchar (max)		Variable-length, standard character string data. n defines the string length and can be a value from 1 through 8,000.
Float	-	Float	Numeric , zero, or NULL value	Uses the floating-point numbers with 16 or fewer significant digits
Integer	Int	Int	Numeric, zero, or NULL value	Stores whole numbers (no decimal point)
NVarchar [ ( n   max ) ]	-	NVarchar(n) or NVarchar(max)	A character string, blank space (s) or NULL value	Variable-length Unicode character data. N can be a value from 1 through 4,000.

#### References

The primary references related to this document are located on the OCC website: <a href="mailto:cancer.gov">cancer.gov</a> site references:

- CCSG Data Guide
- eData
- Download eData Templates
- ICD10
- FAQ

# SECTION 1. DATA TABLES 1A, 1B, 1C, AND 1D

#### 1.1 Data Table 1A - Senior Leadership

Create one record for each individual senior leader and use the following column name and definitions for clarity and uniformity:

**Table 1-1: Data Table 1A Column Definitions** 

Column Name	SQL-Server Data Type	Definition
FY	Int YYYY	The fiscal year for which the Data Tables are being submitted; it can be from October 1 of the prior year through September 30 of the year being funded. ( <i>e.g.</i> , 2014)
GrantNumber	Varchar(25)	The grant application identification number (e.g., 123456)
ReportingDate	DateTime MM/DD/YYYY	Center-defined reporting date
LastName	Varchar(25)	The last name of the senior leader
FirstName	Varchar(25)	The first name of the senior leader
MiddleName	Varchar(25)	The middle name or initial of the senior leader
IsNew	Char(1)	Indicate whether this is a new leader since the last application was submitted; use "Y" for yes and "N" for no.
Title	Varchar(100)	The title of the senior leader
Degree1	Varchar(15)	First academic degree acronym or abbreviation of the senior leader ( <i>e.g.</i> , PhD)
Degree2	Varchar(15)	Second academic degree acronym or abbreviation of the senior leader (leader (e.g., MD)
Degree3	Varchar(15)	Third academic degree acronym or abbreviation of the senior leader (leader (e.g., MS)
Comments	Varchar(8000)	Optional free text field that allows user to enter notes or remarks on the current record.

Data example format can be found in this section Data Table 1A Example Format

#### 1.2 Data Table 1B - Programs, Leaders, and Program Codes

Create one record for each research program; use the following column names and definitions for clarity and uniformity.

For research program with multiple leaders, please add seven additional fields per additional leader, for instance, LastNameN, FirstNameN, MiddleNameN, DegreeN1, DegreeN2, DegreeN3, isNewN. N is a numeric value that is great than 1.

**Table 1-2: Data Table 1B Column Definitions** 

Column Name	SQL-Server Data Type	Definition	
FY	Int YYYY	The annual period for which the Data Tables are being submitted; it can be from October 1 of the prior year through September 30 of the year being described. ( <i>e.g.</i> , 2014)	
GrantNumber	Varchar(25)	The grant application identification number (e.g., 123456)	
ReportingDate	DateTime MM/DD/YYYY	Center-defined reporting date	
ProgCode	Varchar(5)	The alphanumeric code that identifies the clinical research program. This code is also defined in Data Tables 2 and 4 ( <i>e.g.</i> , 01, 02, XT, or BC)	
ProgName	Varchar(255)	The name of the research program	
IsNewProg	Char(1)	Indicate whether this is a new research program since the last application was submitted; use 'Y' for yes and 'N' for no.  Note that Research Programs are peer-reviewed components of the CCSG. Therefore, they cannot be added or deleted during a non-competing (Type 5) year without prior approval from the NCI's Office of Cancer Centers (OCC). If your Center is considering a change in Programs during a non-competing year, please contact your Program Officer.	
IsDevProg	Char(1)	Indicate whether if the research program listed is supported by developmental funds; use 'Y' for yes and 'N' for no	
IsMultiLeader	Char(1)	Indicate whether if this is a multiple leader program; use 'Y' for yes and 'N' for no	
LastName	Varchar(25)	The last name of the primary research program leader	
FirstName	Varchar(25)	The first name of the primary research program leader	
MiddleName	Varchar(25)	The middle name or initial of the primary research program leader	
Degree1	Varchar(15)	First academic degree acronym or abbreviation of the leader (e.g., PhD)	
Degree2	Varchar(15)	Second academic degree acronym or abbreviation of the leader (e.g., MD)	
Degree3	Varchar(15)	Third academic degree acronym or abbreviation of the leader (e.g., MS)	
IsNewLeader	Char(1)	Indicate whether this is a new leader since the last application was submitted; use 'Y' for yes and 'N' for no	

Column Name	SQL-Server Data Type	Definition
LastName2	Varchar(25)	The last name of the secondary research program leader
FirstName2	Varchar(25)	The first name of the secondary research program leader
MiddleName2	Varchar(25)	The middle name or initial of the secondary research program leader
Degree21	Varchar(15)	First academic degree acronym or abbreviation of the director (e.g., PhD)
Degree22	Varchar(15)	Second academic degree acronym or abbreviation of the director (e.g.,
		MD)
Degree23	Varchar(15)	Third academic degree acronym or abbreviation of the director (e.g., MS)
NewLeader2	Char(1)	Indicate whether this is a new leader since the last application was
		submitted; use 'Y' for yes and 'N' for no
NoOfMember	Int	The number of members assigned to the research program including
		Program Leader(s). Members in more than one program should be
		counted once.
Comments	Varchar(8000)	Optional free text field that allows user to enter notes or remarks on the
Comments	vaichai(0000)	current record.

Data example format can be found in this section Data Table 1B Example Format

#### 1.4 Data Table 1C - Shared Resources

Create one record for each shared resource and use the following column names and definitions for clarity and uniformity.

For shared resources with multiple leaders, please add seven additional fields per additional leader, for instance, LastNameN, FirstNameN, MiddleNameN, DegreeN1, DegreeN2, DegreeN3, isNewN. N is a numeric value that is great than 1.

Table 1-4: Data Table 1D Column Definitions

Column Name	SQL-Server Data Type	Definition
FY	Int YYYY	The annual period for which the Data Tables are being submitted; it can be from October 1 of the prior year through September 30 of the year being described. ( <i>e.g.</i> , 2014)
GrantNumber	Varchar(25)	The grant application identification number (e.g., 123456)
ReportingDate	DateTime MM/DD/YYYY	Center-defined reporting date
SRName	Varchar(255)	The name of the shared resource.
SRSubCat1	Float	A 3-digit codes to indicate the shared resource subcategory (e.g., 1.37)
SRSubCat2	Float	A 3-digit codes to indicate the shared resource subcategory ( <i>e.g.</i> , 2.10)
SRSubCat3	Float	A 3-digit codes to indicate the shared resource subcategory (e.g., 7.04)
isNewSR	Char(1)	Indicate whether this is a new Shared Resource since the last application was submitted; use 'Y' for yes, and 'N' for no.  Note that Shared Resources are peer-reviewed components of the CCSG. Therefore, they cannot be added or deleted during a non-competing (Type 5) year without prior approval from the NCI's Office of Cancer Centers (OCC). If your Center is considering a change in Shared Resources during a non-competing year, please contact your Program Officer.
IsDevSR	Char(1)	Indicate whether if the shared resource listed is supported by developmental funds; use 'Y' for yes and 'N' for no
IsMultiDirector	Char(1)	Indicate whether this shared resource is managed by multiple directors. Use 'Y' for yes and 'N' for no
LastName	Varchar(25)	The last name of the primary shared resource director
FirstName	Varchar(25)	The first name of the primary shared resource director
MiddleName	Varchar(25)	The middle name or initial of the primary shared resource director

Column Name	SQL-Server Data Type	Definition
Degree1	Varchar(15)	First academic degree acronym or abbreviation of the primary director ( <i>e.g.</i> , PhD)
Degree2	Varchar(15)	Second academic degree acronym or abbreviation of the primary director ( <i>e.g.</i> , MD)
Degree3	Varchar(15)	Third academic degree acronym or abbreviation of the primary director ( <i>e.g.</i> , MS)
isNewDirector	Char(1)	Indicate whether this is a new director since the last application was submitted; use 'Y' for yes and 'N' for no
LastName2	Varchar(25)	The last name of the secondary shared resource director
FirstName2	Varchar(25)	The first name of the secondary shared resource director
MiddleName2	Varchar(25)	The middle name or initial of the secondary shared resource director
Degree21	Varchar(15)	First academic degree acronym or abbreviation of the secondary director ( <i>e.g.</i> , PhD)
Degree22	Varchar(15)	Second academic degree acronym or abbreviation of the secondary director ( <i>e.g.</i> , MD)
Degree23	Varchar(15)	Third academic degree acronym or abbreviation of the secondary director ( <i>e.g.</i> , MS)
isNewDirector2	Char(1)	Indicate whether this is a new director since the last application was submitted; use 'Y' for yes and 'N' for no
Comments	Varchar(8000)	Optional free text field that allows user to enter notes or remarks on the current record.

Data example format can be found in this section <u>Data Table 1D Example Format</u>

# SECTION 2. DATA TABLES 2A AND 2B - ACTIVE FUNDED PROJECTS

#### 2.1 Data Table 2A - Active Funded Projects

For a center-defined reporting date, create one record for each funded project and use the following column names and definitions.

For multi-PI or multi-investigator grants, please add three additional fields per additional leader, for instance, LastNameN, FirstNameN, MiddleNameN. N is a numeric value that is great than 1.

**Table 2-1: Data Table 2A Column Definitions** 

Column Name	SQL Server Data Type	Definition
FY	Int YYYY	The annual period for which the Data Tables are being submitted; it can be from October 1 of the prior year through September 30 of the year being described. ( <i>e.g.</i> , 2014)
GrantNumber	Varchar(25)	The P30 grant application identification number (e.g., 123456)
ReportingDate	DateTime MM/DD/YYYY	Center-defined reporting date
LastName	Varchar(25)	The last name of the PI from your Center who is responsible for this project
FirstName	Varchar(25)	The first name or initial of the PI from your Center who is responsible for this project
MiddleName	Varchar(25)	The middle name or initial of the PI from your Center who is responsible for this project
IsMultiPI	Char(1)	Indicate whether it is a multi-PI grant; use "Y" for yes and "N" for no.  According to NIH's definition  (http://grants.nih.gov/grants/multi_pi/faq.htm#a1) multiple PIs have equal authority for the grant or contract and are jointly responsible for the scientific and technical direction of the project.
isMultiInvst	Char(1)	Indicate whether it is a multi-investigator grant; use "Y" for yes and "N" for no.  For the purpose of Data Table 2A (DT2A), multiple investigators refer to the investigators of the sub-projects for grants such as SPORE, P50, P01 and so on. These investigators may not be recognized in the NIH grants system as PIs; however we're still identifying them in DT2A.

Column Name	SQL Server	Definition
L	Data Type	
isPeerRev	Char(1)	Indicate whether the Projects that are awarded by NCI, NIH, or organizations with peer-review funding systems as listed on the OCC website; use "Y" for yes and "N" for no.
isSubContract	Char(1)	Indicate whether the project is a subcontract; use "Y" for yes and "N" for no.  Note that # is used in the CCSG Data Guide
FundingSource	Varchar(100)	The specific name of the financial sponsor for the project (e.g., NCI, ACS)
ProjNo	Varchar(100)	Commonly referred to as the application number or grant number. This unique identification number for the grant is composed of the type code, activity code, Institute code, serial number, support year, and/or suffix code ( <i>e.g.</i> , 1R01CA059736-01)
ProjStartDate	DateTime MM/DD/YYYY	Official date a grant award begins; same as the first day of the first budget period ( $e.g.$ , $6/1/2010$ )
ProjEndDate	Date/Time MM/DD/YYYY	Official date a grant award ends; same as the last day of the final budget period. ( <i>e.g.</i> , 5/30/2015)
ProjTitle	Varchar(8000)	The official title of the research project being carried out at your institution ( <i>e.g.</i> , Regulation of mitochondrial inheritance in yeast)
AnnualProjDC	Int	Annual Costs that can be identified specifically with a particular sponsored project, other institutional activity, or that can be directly assigned to such activities relatively easily with a high degree of accuracy (e.g., 1560000)  Do not include a comma (,) or a dollar sign (\$) in the figure.
CARelevantAnnual ProjDC	Int	Estimate, using a method of the Centers devising, the cancer relevant portion of a project and report the funding. Be prepared to defend this estimate in peer-review. For grants that are 100% cancer-relevant (such as all NCI grants), this will be identical with the Annual Project Direct Costs.
ProgCode	Varchar(15)	An alphanumeric code that identifies Research Program affiliated with the clinical research study as defined by the Center in Data Table 1B (e.g., 42, XY) Identify all training grants, including the F, K and T series NIH grants, with the program code "T".
ProgPercent	Int	The proportion of research attributable to the identified Research Program (e.g., 20, 100).  Do not include the percent sign (%) in the figure.
AnnualProgDC	Int	Annual Direct Costs that support research carried out in the Center's Research Programs (e.g., 1560000)  Do not include a comma (,) or a dollar sign (\$) in the figure.

Column Name	SQL Server Data Type	Definition
Comments	Varchar(8000)	Optional free text field that allows user to enter notes or remarks on the current record.

Data example format can be found in this section <u>Data Table 2A Example Format.</u>

#### 2.2 Data Table 2B- Active Funded Projects

List the total number of projects and the sum of direct for each major funding agency category as follows: NCI Peer-Reviewed, Other NIH Peer-Reviewed, Other Peer-Reviewed; and Industry Non Peer-Reviewed and Other Non-Peer Reviewed Projects.

**Table 2-2: Data Table 2B Column Definitions** 

Column Name	SQL-Server Data Type	Definition
FY	Int YYYY	The annual period for which the Data Tables are being submitted; it can be from October 1 of the prior year through September 30 of the year being described. ( <i>e.g.</i> , 2014)
P30GrantNumber	Varchar(25)	The full P30 grant application identification number ( <i>e.g.</i> , 5-P30-CA123456-38)
ReportingDate	DateTime MM/DD/YYYY	Center-defined reporting date
NCIPRTotalNo	Int	The total number of NCI Peer-Reviewed projects
NCIPRDC	Int	The direct cost amount of the NCI Peer-Reviewed projects
OthNIHPRTotalNo	Int	The total number of NIH Peer-Reviewed projects
OthNIHPRDC	Int	The direct cost amount of the NIH Peer-Reviewed projects
OthPRTotalNo	Int	Total number of the other Peer-Reviewed projects
OthPRDC	Int	The direct cost amount of the Other Peer-Reviewed projects
IndNonPRTotalNo	Int	The total number of Industry Non Peer-Reviewed projects
IndNonPRDC	Int	The direct cost amount of the Industry Non Peer-Reviewed projects
OthNonPRTotalNo	Int	The total number of the other Non-Peer-Reviewed projects
OthNonPRDC	Int	The direct cost amount of the other Non-Peer-Reviewed projects
Comments	Varchar(8000)	Optional free text field that allows the user to enter any remark about the current record or row of data.

Data example format can be found in this section <u>Data Table 2B - Format Sample</u>.

# SECTION 3. DATA TABLE 3 - NEWLY REGISTERED PATIENTS/PARTICIPATION OF PATIENTS IN INTERVENTIONAL TREATMENT TRIALS BY ANATOMIC CANCER SITE

For the 12-month period as defined by the Cancer Center, create one record for reportable cancers and use the following column names and definitions for clarity and uniformity.

**Note to Consortium Cancer Centers and Cancer Centers with affiliated institutions:** Submit separate Data Table 3 tables for each consortium partner and/or affiliated institution (*e.g.*, pediatric hospital) that is a formal component of the Cancer Center but maintains a separate cancer registry. Do not include loosely affiliated community partners.

**Table 3-1: Data Table 3 Column Definitions** 

Column Name	SQL-Server Data Type	Definition							
FY	Int YYYY	The annual period for which the Data Tables are being submitted; it can be from October 1 of the prior year through September 30 of the year being described. ( <i>e.g.</i> , 2014)							
GrantNumber	Varchar(25)	The P30 grant application identification number ( <i>e.g.</i> , 123456)							
ReportingSource	Varchar(255)	Name of Reporting Source. For consortium centers or those with affiliated institutions, indicate the specific name of the reporting institution.							
ReportingStartDate	DateTime MM/DD/YYYY	The date on which the center-defined 12-month reporting period started							
		The date on which the center-defined 12-month reporting period ended							
PrimarySite	Varchar(255)	Reportable Cancers. Malignancies with an International Classification of Diseases for Oncology (ICD) behavior code of 2 or 3 should be reported, in accordance with the established requirements of registry standard setting organizations. Please refer to the ICD Codes on the OCC website ICD10.							

Column Name	SQL-Server Data Type	Definition
NewlyRegisteredPatient	Int	Newly registered patients are those patients seen face-to- face and recorded in the Cancer Center's Cancer Registry for the first time for that diagnosis during the reporting period. They include inpatients and outpatients who:
		1) are newly diagnosed and/or receiving first course of treatment at the Cancer Center, <i>i.e.</i> , equivalent to American College of Surgeons-defined analytic case codes $00 - 22$ FORDS-2016
		2) have recurrent or persistent disease and are referred to the Cancer Center for evaluation and treatment, <i>i.e.</i> , equivalent to American College of Surgeons-defined non-analytic code 32.
Comments	Varchar(8000)	Optional free text field that allows user to enter notes or remarks on the current record.

# **Data Table 3 - Example Format**

Data Table 3 – Newly Registered Patients /Participation in Interventional Treatment Trials by Anatomic Cancer Site

FY	Grant Number	ReportingSource	ReportingSource Reporting StartDate		PrimarySite	Newly Registered Patient	Comments		
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Lip, Oral Cavity and Pharynx	85			
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Esophagus	62			
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Stomach	181			
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Small Intestine	0			
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Colon	728			
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Rectum	50			
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Anus	9			
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Liver	121			
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Pancreas	52			
2023	123456	1 '   '		Other Digestive Organ	174				
2023	123456	My Cancer Center         01/01/2022         12/31/2022         Larynx           My Cancer Center         01/01/2022         12/31/2022         Lung		Larynx	50				
2023	123456	My Cancer Center 01/01/2022 12/31/2022 I			1257				
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Other Respiratory and Inthrthoracic Organs	105			
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Bones and Joints	25			
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Soft Tissue	35			
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Melanoma, skin	81			
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Kaposi's sarcoma	21			
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Mycosis Fungoides	23			
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Other Skin	6			
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Breast	1203			
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Cervix	60			
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Corpus Uteri	602			
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Ovary	49			
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Other Female Genital	33			
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Prostate	382			
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Other Male Genital	22			
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Bladder	188			
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Kidney	183			
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Other Urinary	10			
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Eye and Orbit	6			
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Brain & Nervous System	932			
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Thyroid	188			
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Other Endocrine System	21			
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Non-Hodgkin's Lymphoma	190			
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Hodgkin's Lymphoma	10			

FY	Grant Number	ReportingSource	Reporting StartDate	Reporting EndDate	PrimarySite	Newly Registered Patient	Comments
2023	123456			Multiple Myeloma	307		
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Lymphoid Leukemia	37	
2023	123456	My Cancer Center	1 1 1		Myeloid and Monocytic Leukemia	154	
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Leukemia, other	1	
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Other Hematopoietic	83	
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Unknown Sites	118	
2023	123456	My Cancer Center	01/01/2022	12/31/2022	Ill-Defined Sites	3	

<sup>\*</sup> Please use these predefined Primary Site categories as listed. Altering the list will make processing the data less efficient.

# SECTION 4. DATA TABLE 4 - INFORMATION ON CLINICAL RESEARCH STUDIES

Create one record for each clinical research study and use the following column names and definitions for clarity and uniformity.

**Table 4-1: Data Table 4 Column Definitions** 

Column Name	SQL-Server Data Type	Definition						
FY	Int YYYY	The annual period for which the Data Tables are being submitted; it can be from October 1 of the prior year through September 30 of the year being described. ( <i>e.g.</i> , 2014)						
GrantNumber	Varchar(25)	The P30 grant application identification number (e.g., 123456)						
ReportingStartDate	DateTime MM/DD/YYY Y	The date on which the center-defined 12-month reporting period started						
ReportingEndDate	DateTime MM/DD/YYY Y	The date on which the center-defined 12-month reporting period ended						
ClinicalResearchCat	Varchar(15)	The Clinical Research Category in which the clinical research or protocol is listed Valid entry: INT, OBS, or ANC/COR						
StudySource	Char(1)	The category of the trial sponsor or Study Source Valid entry: N, E, I, or D N - National Cooperative group E - Externally Peer-Reviewed I - Institutional D - Industry						
FundingSource	Varchar(100)	The specific name of the financial sponsor for the clinical research study. For institutionally sponsored trials or studies, list the name of the applicable funding agencies, ( <i>e.g.</i> , NCI, NYU)						
PrimarySite	Varchar(255)	The primary anatomic cancer site(s) ( <i>i.e.</i> , breast, ovary) the clinical research study focuses on. If the clinical research study is broadly applicable to a number of potential anatomic sites, enter the term "multiple" in this column.						

Column Name	SQL-Server Data Type	Definition							
NCTID	Varchar(50)	The unique ID assigned to the trial by the National Clinical Trial program (ClinicalTrials.gov) for trials that have been submitted to ClinicalTrials.gov Protocol Registration System (PRS) previously. This ClinicalTrials.gov ID appears as "NCT" followed by 8 numeric characters (such as NCT12345678). (i.e., NCT00009876); If it is not applicable, use the ProtocolID.							
ProtocolID	Varchar(50)	The unique identifier for the study. List the common protocol number that the trial is known under nationally, if one exists. For other trials that do not have an NCT number or a common protocol number that the trial is known under nationally, use an internal protocol identification or IRB number.							
OthProtocolID	Varchar(50)	Additional IDs assigned to the trial, including the following: NCI, CTEP or DCP, unique IDs from other registries, Protocol numbers assigned by the review board, other IDs							
LocalTrialID	Varchar50)	The unique ID assigned at the Cancer Center level and used at the sites level to identify a trial.							
NCIID	Varchar50)	The unique ID assigned to the trial by the CTRP.							
IsMultiInst	Char(1)	Indicate whether the study is a multiple institutions; use "Y" for yes and "N" or (leave blank) for no.							
LastName	Varchar(25)	The last name of the Principal Investigator from your Center who is responsible for this Clinical Research Study							
FirstName	Varchar(25)	The first name or initial of the Principal Investigator from your Center who is responsible for this Clinical Research Study <i>Do not include a period (.)</i>							
MiddleName	Varchar(25)	The middle name or initial of the Principal Investigator from your Center who is responsible for this Clinical Research Study <i>Do not include a period (.)</i>							
ProgCode	Varchar(5)	An alphanumeric Program Code that identifies the Research Program affiliated with the clinical research study as defined by the Center in Data Tables 1B and 2A. For clinical research studies that span more than one Research Program, include both Program Codes in this column.  Refer to the Falls, R. example in the CCSG Data Guide							

Column Name	SQL-Server Data Type	Definition							
OpenDate	DateTime MM/DD/YYYY	The official start date of a trial at your Center determined by 1) to date of activation noted in an official clinical trial activation announcement or 2) date of first patient accrual if the trial in question did not have a formal activation announcement. This value on CTRP DT4 is determined by the earliest "open" status date at any site associated with the center on the trial. The following trial statuses reflect an "open" status in CTRP: Active Enrolling by Invitation, Available, Temporarily Closed to Accrual and Intervention.							
OpenDate CloseDate	DateTime MM/DD/YYYY	The date the clinical research study closed to accrual. This does not include patient follow-up. If the study is still open, this field will be blank/null.  This value on the CTRP-generated DT4 is determined by the latest "closed" date at any site associated with the cancer center on the trial. The following statuses reflect a "closed" status in CTRP: Closed to Accrual, Closed to Accrual and Intervention, Complete, Administratively Complete or Withdrawn.							
Phase	Varchar(255)	Early Phase I: Exploratory trials, involving very limited human exposure, with no therapeutic or diagnostic intent (e.g., screening studies, microdose studies). See FDA guidance on exploratory IND studies for more information.  I: Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.  I/II: Trials that are a combination of phases 1 and 2.  II: Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.  II/II: Trials that are a combination of phases 2 and 3.  III: Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.  IV: Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.  N/A: Trials without phases (for example, studies of devices or behavioral interventions).  Note: do not include blank spaces.							

Column Name	SQL-Server Data Type	Definition						
IsPilot	Char(1)	Pilot attribute can be assigned to any phase. Indicate whether						
		the study is a pilot phase; use "Y" for yes and "N" for no.						
PrimaryPurpose	Varchar(3)	The type or primary purpose of clinical trial.						
		Primary purpose the trial, as follows:						
		Tre: Treatment						
		Pre: Prevention						
		Sup: Supportive Care						
		Scr: Screening						
		Dia: Diagnostic						
		Hsr: Health Services Research						
		Bas: Basic Science						
		Dev: Device Feasibility						
		Oth: Other						
		Valid entry: Tre, Pre, Sup, Scr, Dia, Hsr, Bas, Dev, or Oth.						
		Indicate whether the trial is pragmatic; use "Y" for yes and "N" or						
Prag	Char(1)	(leave blank) for no.						
		See CCSG Data Guide for the definition.						
OfficialTitle	Varchar(8000)	Official name of the protocol provided by the study principal						
		investigator or sponsor (Limit: 600 characters or fewer).						
EntireStudy	Int	The total targeted accrual for the entire study. For both single-site						
		and multi-site trials initiated at your Center, indicate the total						
		number of participants needed for the entire study. For multi-site						
		trials that your Center participates in but did not initiate, leave this						
		column empty.						
		Do not submit a targeted range, such as "10 – 100."						
YourCenterTotal	Int	The targeted accrual for your Center. For single-site and multi-site						
		trials initiated at your Center, indicate the total number of						
		participants your Center is expected to accrue for the study.						
		Do not submit a targeted range, such as "10 – 100."						
Center12Mos	Int	Provide the number of participants accrued to this clinical research						
		study during the identified 12-month reporting period study your						
		Cancer Center and its formal Consortium Partners.						
CenterToDate	Int	Provide the number of participants accrued to this clinical research						
		study to date at your Cancer Center and its formal Consortium						
		Partners. This number is a cumulative figure, not an annual total.						

Column Name	SQL-Server Data Type	Definition
Other12Mos	Int	Provide the number of participants accrued to this clinical research
		study during the identified 12-month reporting period at all
		hospitals, treatment facilities, and/ or research facilities that are a
		formal part of the Cancer Center (e.g., nearby community
		hospitals).
OtherToDate	Int	Provide the number of participants accrued in the clinical research
		study to date at all hospitals, treatment facilities, and/ or research
		facilities that are a formal part of the Cancer Center (e.g., nearby
		community hospitals).
		This number is a cumulative figure, not an annual total.
10.0		If the Lead Organization, column is populated with a summary
		of accrual for all participating sites on the trial through the last
EntireStudyAccrualToDate	Int	day of the reporting period (directly and not directly connected
		to the Lead Organization CTRP Family).
		If a Participating Site, column is blank.
Comments	Varchar(8000)	Optional free text field that allows user to enter notes or remarks
Comments	v archar(6000)	on the current record.

Data example format can be found in this section <u>Data Table 4 - Format Sample.</u>

CCSG Electronic Data Guide (eI	)ata)	Joto'	$\alpha$ ( $\alpha$ I	Guida	Doto	Floatronia	CCCC

APPENDIX A. DATA TABLE EXAMPLE FORMAT

# **Data Table 1A Example Format**

# Data Table 1A- Senior Leadership

FY	GrantNumber	ReportingDate	LastName	FirstName	MiddleName	IsNew	Title	Degree1	Degree2	Degree3	Comments
2023	123456	01/01/2022	Sutton	Baylor	T	N	Director and Principal Investigator	MD	PhD		
2023	123456	01/01/2022	Marucco	Gina	Elizabeth	N	Deputy Director	PhD			
2023	123456	01/01/2022	Galley	Mark		N	Assoc. Director for Basic Science	MD			
2023	123456	01/01/2022	Barrie	Thomas	Ellen	Y	Assoc. Director for Clinical Research	MD	PhD	MS	
2023	123456	01/01/2022	Wong	Lee	Q.	N	Assoc. Director for Population Research	PhD			

#### **Data Table 1B Example Format**

Data Table 1B – Programs Leaders

FY	Grant Number	Reporting Date	Prog Code		Is New Prog	Is Dev Prog	ls Multi Leader	Last Name	First Name	Middle Name	Degree1	Degree2	Degree3	isNewLeader		First Name	Middle Name	Degree21	Degree22	Degree23	IsNewLeader2	NoOfMember	Comments
2023	123456	01/10/2022	01	Molecular and Cellular Biology				Harrington	Marc	F.	MD	PhD										25	
2023	123456	01/10/2022	02	Cancer Control and Prevention	Y			Pham	Phuong	Duong	PhD											14	
2023	123456	01/10/2022	03	Epidemiology				Kaufman	Richard	W.	MD	PhD										19	
2023	123456	01/10/2022	04	Developmental Therapeutics			Y	Wood	Mary		MD	PhD			Storm	John		PhD			Y	15	
2023	123456	01/10/2022	05	Women's Cancers				Miller	Barbara	Jasmine	PhD										2	22	
2023	123456	01/10/2022	CCG	Cell Cycle and Growth Control				Neuhauser	Beverly													12	
2023	123456	01/10/2022	IM	Immunology				Bhorjee	Jaswant	S.	MD	PhD		Y							1	27	
2023	123456	01/10/2022	ZY	Non-Aligned Members																		12	

Note: Some of the names of the columns are displayed vertically in order to fit in one page for examples purpose only.

#### **Data Table 1C Example Format**

Data Table 1C - Shared Resources

FY	Grant Number	Reporting Date	SRName	Sub Cat1	Sub Cat2	Sub Cat3		Is Dev SR	IsMultiDirector	Last Name	First Name	Middle Name	Degree1	Degree2	Degree3	IsNewDirector	Last Name2	First Name2	Middle Name2	Degree21	Degree22	Degree23	IsNewDirector2	Comments
2023	123456	01/10/2022	Biostatistics	6.01			N	N	N	Francini	Benjamin		PhD			Y			1	1.1				
2023	123456	01/10/2022	DNA Sequencing	1.22	1.35		N	N	N	Kelley	Steven		MD	PhD		N							П	
2023	123456	01/10/2022	Genomics and Proteomics	1.36			Y	N	N	Goldstein	Phillip		PhD			N							I	
2023	123456	01/10/2022	Bioinformatics	7.02			N	N	N	Mayrend	Jody	Kim	MD	PhD		N								
2023	123456	01/10/2022	Organic Synthesis	1.12			N	N	N	Singer	Richard		MD	PhD		Y								
2023	123456	01/10/2022	Transgenic Animal Facility	1.03	1.06	1.09	N	N	Y	Peterson	Douglas	John	MD			N	Barns	Nancy		MD		]	N	

Note: Some of the column names are displayed vertically to fit in one page for the example purpose only.

# **Data Table 2A - Example Format**

## Data Table 2A – Active Funded Projects

FY	GrantNumber	ReportingDate	Last Name	First Name	MiddleName	Last Name 2	First Name 2	MiddleName2	isMultiPI	isMultiInvest	isPeerRev	isSubContract	Funding Source	Proj No	ProjStartDate	ProjEndDate	Proj Title	Annual Proj DC	CARelevantAn nualProjDC	ProgCode	ProgPercent	Annual Prog DC	Comments
2023	123456	03-01-2018	Alfred	Leon							Y		NCI	1R01CA05 9736-01	06-01-2014	05-30-2023	Triterpenoids as chemopreventive agents	200,000	200,000	4	100	200,000	
2023	123456	03-01-2018	Dubois	Yvette							Y		NCI	5R01CA06 7893-02	09-01-2012	08-03-2023	Star trial (Tamoxifen vs. Raloxifene)	100,000	100,000	1	60	60,000	
2023	123456	03-01-2018	Dubois	Yvette							Y		NCI	5R01CA06 7893-02	09-01-2012	08-03-2023	Star trial (Tamoxifen vs. Raloxifene)			5	40	40,000	
2023	123456	03-01-2018	Birmann	Brad		Glick	Darian		Y		Y		NINDS	1R01NS04 6045-03	03-01-2013	02-28-2018	Targeting the anti- apoptotic protein surviving in glioma	300,000	300,000	СВ	100	300,000	
2023	123456	03-01-2018	Bhorjee	Jacob		Vembu	Dana		Y		Y		NHLBI	1R01HL05 6899-01	05-01-2015	04-20-2030	Natural ligands of the aryl hydrocarbon receptor	400,000	300,00	МСВ	50	150,000	

FY	GrantNumber	Last Name	First Name	MiddleName	Last Name 2	First Name 2	MiddleName2	isMultiPI	isMultiInvest	isPeerRev	isSubContract	Funding Source	Proj No	ProjStartDate	ProjEndDate	Proj Title	Annual Proj DC	CARelevantAn nualProjDC	ProgCode	ProgPercent	Annual Prog DC	Comments
2023	123456							Y		Y		NHLBI	1R01HL05 6899-01	05-01-2015	04-20-2030	Natural ligands of the aryl hydrocarbon receptor			ET	50	150,000	
2023	123456	Michaels	Helen		Herman	Beth		Y		Y		NCI	2R01CA87 6-098-02	12-01-2013	11-30-2018	Southern Community Cohort	300,000	300,000	Ері	100	300,000	
2023	123456	Donegan	Alex							Y	Y	NHLBI Dartmouth	3R01HL08 685-03S2	08-01-2012	07-03-2023	Calpain and p120 catenin regulation of cadherin function	50,000	50,000	3	100	50,000	
2023	123456	Wang	Thomas							Y	Y	NCI	3R01CA07 196-03	08-01-2012	07-30-2023	Southern Community Cohort Study	775,000	775,000	3	100	775,000	
2023	123456	Persky	Dawn							Y		NCI	S1001	07-18-2011	06-30-2014	A Phase II Trial of R-CHOP followed by Yttrium-90 Ibritumomab tiuxetan for Early Stage Diffuse Large B- cell Lymphoma	215,000	215,000	5	100	215,000	
2023	123456	Lee	Rich						Y	Y		NCI	5P50CA11 9997-04	03-01-2012	02-28-2023	SPORE in Lung Cancer	1,250,000	1,250,000				

FY	GrantNumber	ReportingDate	Last Name	First Name	MiddleName	Last Name 2	First Name 2	MiddleName2	isMultiPI	isMultiInvest	isPeerRev	isSubContract	Funding Source	Proj No	ProjStartDate	ProjEndDate	Proj Title	Annual Proj DC	CARelevantAn nualProjDC	ProgCode	ProgPercent	Annual Prog DC	Comments
2023	123456	03-01-2018	Lee	Rich						Y	Y		NCI	5P50CA11 9997-04	03-01-2012	02-28-2023	SPORE in Lung Cancer Project 1: Anti-tumor Mechanisms of SRC Inhibitors in Lung Cancer			2	100	250,000	
2023	123456	03-01-2018	Lee	Rich						Y	Y		NCI	5P50CA11 9997-04	03-01-2012	02-28-2023	SPORE in Lung Cancer Core C: Administration and Patient Advocacy		40,000	ZY	100		
2023	123456	03-01-2018	Uriel	Grant						Y	Y			5P50CA11 9997-04									
2023	123456	03-01-2018	Lee	Rich						Y	Y		NCI	5P50CA11 9997-04	03-01-2012	02-28-2023	SPORE in Lung Cancer: Core A: Tissue Procurement, Pathology, and Bioinformatics		300,000	ZY	100		
2023	123456	03-01-2018	Jackson	Abraham						Y	Y			5P50CA11 9997-04									
2023	123456	03-01-2018	Lee	Rich						Y	Y		NCI	5P50CA11 9997-04	03-01-2012	02-28-2023	SPORE in Lung Cancer Project. 2: E2F's Impact on Therapeutic Efficacy			1	100	200,000	

FY	GrantNumber	ReportingDate	Last Name	First Name	MiddleName	Last Name 2	First Name 2	MiddleName2	isMultiPI	isMultiInvest	isPeerRev	isSubContract	Funding Source	Proj No	ProjStartDate	ProjEndDate	Proj Title	Annual Proj DC	CARelevantAn nualProjDC	ProgCode	ProgPercent	Annual Prog DC	Comments
2023	123456	03-01-2018	Sherman	William						Y	Y			5P50CA11 9997-04									
2023	123456	03-01-2018	Smith	Ellen						Y	Y			5P50CA11 9997-04									
2023	123456	03-01-2018	Lee	Rich						Y	Y			5P50CA11 9997-04	03-01-2012	02-28-2023	SPORE in Lung Cancer: Project. 3: RRM1 in the Management of Lung Cancer			1	100	360,000	
2023	123456	03-01-2018	Stuart	James						Y	Y			5P50CA11 9997-04									
2023	123456	03-01-2018	Pope	Beatrice									Vical	N/A	7-01-2014	12-21-2016	Phase II Trial of Allovectin-7 for Metastatic Melanoma	250,000		4	100	250,000	

Note: Some of the names of the columns are displayed vertically in order to fit across one page for example purposes only.

#### **Data Table 2B Example Format**

#### 2P30CA123456-09

#### Data Table 2B – Active Funded Projects

I	ΥY	P30Grant Number	Reporting Date	NCI PR Total No	NCIPR DC	OthNIH PR Total No	_ nn	OthPR TotalNo	OthPR DC	Ind NonPR TotalNo	Ind NonPR DC	Oth NonPR TotalNo	Oth NonPR DC	Oth NonPR TC	Comments
20	023	2P30CA123456-09	01/01/2022	13	5180000	9	1916000	5	2377000	2	325000	4	1706900	1313000	

Note that a full P30 grant number is requested for DT2B.

#### **Data Table 4 - Example Format**

Data Table 4 - Clinical Research Protocols

FY	GrantNumber	ReportingStartDate	ReportingEndDate	Clinical Research Cat	StudySource	Funding Source	Primary Site	NCT Number	Protocol ID	IsMultiInst	Last Name	First Name	Middle Name	ProgCode	OpenDate	CloseDate	Phase	PrimaryPurpose	OfficialTitle	EntireStudy	YourCenterTotal		Center ToDate	12mos	Other To Date	EntireStudyAccural ToDate	Comments
2023	123456	01/01/2022	12/31/2022	INT	N	SWOG	Bladder	NCT00123 40712	SWOG- 0712		Armstr ong	С	John	2	8/15/2013		III	Tre	Randomized chemo/rt/surg for bladder cancer		220	82	120				
2023	123456	01/01/2022	12/31/2022	INT	N	Alliance	Myeloid leukemi a	NCT10603 678	10603	Y	Kane	Steve		8	4/21/201		Ш	Tre	Induction & Consolidation Chemo + Midostaurin v Placebo in Newly Diagnosed FLT3 Mutated AML		70	28	49				
2023	123456	01/01/2022	12/31/2022	INT	N	COG	Myeloid leukemi a		COG-08H9	Y	Lehr	D		4	5/1/2012		I	Tre	Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocyti c Leukemia		6	0	4				
2023	123456	01/01/2022	12/31/2022	INT		NYU, NCI	Multiple	NCT00110 912	NCI -1109	Y	Mack	Frank	D	3	8/1/2012		Ш	Sup	Preparatory Aid to Improve Decision Making about Cancer Clinical Trials (PRE-ACT)	500	60	22	46	70	240	535	

FY	GrantNumber	ReportingStartDate	ReportingEndDate	Clinical Research Cat	StudySource	Funding Source	Primary Site	NCT Number	Protocol ID	IsMultiInst	Last Name	First Name	Middle Name	ProgCode	OpenDate	CloseDate	Phase	PrimaryPurpose	OfficialTitle	EntireStudy	YourCenterTotal	Center 12mos	Center ToDate	12mos	Other To Date	EntireStudyAccural ToDate	Comments
2023	123456	01/01/2022	12/31/2022	INT	Е	NCI	Rectum	018	NCI 06-8-01	N	Sheph ard	A		2	12/5/201				Polyethylene Glycol For ACF Reduction and Biomarker Modulation in Individuals with CRC Risk	140	140	34	68			184	
2023	123456	01/01/2022	12/31/2022	INT	I	NYU		NCT00001 054	NYU-1054	N	Allen	Thoma s		2	2/14/201		I/II	Sup	Dose Finding and Tolerability ALA in Paclitaxel Induced Neuropathy Pts.	30	30	4	10			56	
2023	123456	01/01/2022	12/31/2022	INT	I	NYU	Lympho ma	NCT98765 159	NYU-5150	N	Bates	S		4	5/1/2012		I	Tre	Ofatumumab for inindolent B-cell lymphomas		6	0	4				
2023	123456	01/01/2022	12/31/2022	INT	I	NYU		NCT00981 133		Y	Dunn	R	Cherel	1	7/4/2015		II		Restasis Vs Placebo in Primary Prevention of Ocular GVHD	62	6	2	5	2	8	61	
2023	123456	01/01/2022	12/31/2022	INT	I	NYU	Multiple	NCT00120 521	NU-0521	N	Hook	S		10	1/17/201		П		Etanercept in Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor SCT	405	105	10	30			398	

FY	GrantNumber	ReportingStartDate	ReportingEndDate	Clinical Research Cat	StudySource	Funding Source	Primary Site	NCT Number	Protocol ID	IsMultiInst	Last Name	First Name	Middle Name	ProgCode	OpenDate	CloseDate	Phase	PrimaryPurpose	OfficialTitle	EntireStudy	YourCenterTotal	Center 12mos	Center ToDate	12mos	Other To Date	EntireStudyAccural ToDate	Comments
2023	123456	01/01/2022	12/31/2022	INT	D	GSK		NCT00110 806	GSK 0806	N	Day	Patrici a		10	3/1/2013		Ĭ	Sup	Phase 1 Trial of Palifermin for Oral Mucositis	85	15	6	8			34	
2023	123456	01/01/2022	12/31/2022	INT	D	BMS	Lympho id leukemi a	NCT00985 013	DRUG - 5013	N	Head	R		8	5/1/2014		Ш	Tre	Lenalidomide as Maintenance Therapy for Patients with B-cell CLL		113	47	79				
2023	123456	01/01/2022	12/31/2022	OBS	Е			NCT01152 909	NCI-2902	N	Falls	R	D	8 & 10	7/2/2012		N/A	Oth	Neurocogniti ve outcomes in pediatric brain tumor survivors following proton beam XRT vs conventional	400	100	13	30			98	
2023		01/01/2022	12/31/2022	OBS		American Cancer Society	Prostate	NCT01152 152	ACS-2162	Y	Rogers	Seldon		6	9/5/2014		N/A	Oth		80	14	6	8	7	14	62	
2023	123456	01/01/2022	12/31/2022	OBS	Е	NCI		NCT01153 315	NCI-3315	N	Lemon	J	Joseph	3	6/1/2013		N/A	Oth	Exogenous hormone use and risk of ovarian cancer		50	12	49				

FY	GrantNumber	ReportingStartDate	ReportingEndDate	Clinical Research Cat	StudySource	Funding Source	Primary Site	NCT Number	Protocol ID	IsMultiInst	Last Name	First Name	Middle Name	ProgCode	OpenDate	CloseDate	Phase	PrimaryPurpose	OfficialTitle	EntireStudy	YourCenterTotal		Center ToDate	12mos	Other To Date	EntireStudyAccural ToDate	Comments
2023	123456	01/01/2022	12/31/2022	OBS	Ì	NYU		NCT01151 926	NYU-1926	Y	Berry	June		08	5/1/2015		N/A	Oth	Risk factors for childhood cancer and hematological disorders by case- control studies	4000	1500	125	499	86	600	2200	
2023	123456	01/01/2022	12/31/2022	OBS	I	NYU, NIH	Multiple Myelom a	NCT01151 007	NYU-1007	N	Smith	S		08	1/1/2010	4/7/2011	N/A	Oth	Treatment Decision Making in Older Adults Newly Diagnosed with MM		20	6	18				
2023	123456	01/01/2022	12/31/2022	ANC/COR	I	NYU	Brain	NCT01051 762	NYU-1762	N	Okra	Selby		08	2/23/201		N/A		Phase I & 2 drug metabolism polymorphis ms & outcome in children with medulloblasto ma	202	54	10	36			82	
2023	123456	01/01/2022	12/31/2022	ANC/COR	I	NYU		NCT01052 701	NYU-2701	Y	Grang er	I		08	6/15/201		N/A	Bas	Prospective observational trial of telomere length and telomerase mutations in pediatric AML	100	30	12	25	8	18	74	

FY	GrantNumber	ReportingStartDate	ReportingEndDate	Clinical Research Cat	StudySource	Funding Source	Primary Site	NCT Number	Protocol ID	IsMultiInst	Last Name	First Name	Middle Name	ProgCode	OpenDate	CloseDate	Phase	PrimaryPurpose	OfficialTitle	EntireStudy	YourCenterTotal			12mos	Other To Date	EntireStudyAccural ToDate	Comments
2023	123456	01/01/2022	12/31/2022	ANC/COR	I	NYU		NCT01050 631	NYU-0631	N	Down	R	R	08	2/30/201		Ш	Oth	Comparison ofAcute and Long-term Toxicities in BM Donors w/wout G- CSF Treatment Prior to Harvest		206	48	89				
2023	123456	01/01/2022	12/31/2022	ANC/COR	I	NYU	Other hemapoi et ic	NCT01050 890	NYU-0898	N	Gosde n,	Robert		08	2/4/2015		N/A	Bas	Biology Study ofTransient Myeloprolifer ative Disorder (TMD) in Children with Down Syndrome (DS)		17	1	3				

Note: Some of the names of the columns are displayed vertically in order to fit in one page for examples purpose only.

CCSG	Electronic	Data	Guida	(aData)
CCSG	Electronic	Data	Guide	i eData

APPENDIX B. SUMMARY OF CHANGES TO EDATA

Table B-1: Summary of Changes to eData

<b>Updated Date</b>	Effected Data Table(s)	Description of Changes
04/01/2023	DT4	Added a new column "Prag".
08/24/2022	DT3	Fixed broken links to ICD10 and FORDS-2016 in DT3.
02/05/2010	Introduction	Modified Figure 1: The Data Tables Data Flow Diagram
10/30/2022	Introduction	Modified Figure 1: The Data Tables Data Flow Diagram
	DT4	Modified the definition of the OpenDate and CloseDate, added EntireStudyAccrualToDate fields, and modified DT4 Example Format in the Appendix A, page A9-A13.
02/14/2018	DT4	To further harmonize fields and definitions with the ClinincalTrials.gov and CTRP:  Renamed NCINumber to NCIID and modified the definition, modified Phase eliminating phase "0", "Pilot", and "Feasibility" options, modified the definition of the ProtocolID, Other12Mos, and OtherToDate, added "Dev" option to the Primary Purpose, added IsPilot, OtherProtocolID, NCIID, and Local Trial ID fields.
01/24/2023	DT1	Revised 1B "NoOfMember" column definition, eliminated 1C – Program Members, and

<b>Updated Date</b>	Effected Data Table(s)	Description of Changes
		labeled 1D as 1C.
	DT2	Eliminated total costs
	DT2 A and B	Moved all training projects to Cancer Research Career Enhancement and Related Activities.
	DT3	Eliminated "Patients newly accrued to treatment trials", and combined "Female Breast" and "Male Breast" to "Breast".
	DT4	No changes – CTRP will generate DT4 in the future (2018 or later).